行情

APLT

APLT

Applied
NASDAQ

实时行情|Nasdaq Last Sale

10.52
+0.71
+7.24%
已收盘, 16:40 09/20 EDT
开盘
10.25
昨收
9.81
最高
10.84
最低
9.60
成交量
14.38万
成交额
--
52周最高
11.39
52周最低
7.95
市值
1.79亿
市盈率(TTM)
-20.5469
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

APLT 新闻

  • 法国财长:若美国制裁欧盟 欧盟将反击
  • 央视.3天前
  • 隔夜要闻:美股涨跌不一 微软盘中刷新历史新高
  • 新浪美股.3天前
  • 中概股周四收平 流利说连跌三天股价创纪录新低
  • 新浪美股.3天前
  • 市场聚焦沙特供应短缺 美油涨逾1%暂止颓势
  • 汇通网.3天前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

APLT 简况

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). It is also developing AT-001 for diabetic peripheral neuropathy (DPN), a debilitating neurodegenerative disease.
展开

Webull提供Applied Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。